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Abstract
Background: There are no published human studies investigating whether the use of allopurinol, the most commonly
used medication for the treatment of hyperuricemia in gout, the most common type of inflammatory arthritis in adults,
has any beneficial effects on ventricular electrophysiology. The objective of our study was to assess whether allopurinol
use is associated with a reduction in the risk of ventricular arrhythmias (VA).
Methods: We used the 5% random sample of Medicare beneficiaries from 2006–2012 to examine new allopurinol use and
the risk of incident VA. Multivariable Cox regression analyses were adjusted for demographics (age, race, sex), comorbidity,
cardiac medications, and conditions associated with VA. We calculated hazard ratios (HR) and 95% confidence intervals (CI).
Results: Of the 28,755 episodes of new allopurinol use, 2538 were associated with incident VA (8.8%). Among patients
with incident VA, 54% were male, 78% were White, 75% had gout as the underlying diagnosis, and the mean
Charlson–Romano comorbidity score was 4.8. The crude incidence of VA per 1,000,000 person-days declined as the
duration of allopurinol use increased: 1–180 days, 151; 181 days to 2 years, 105; and > 2 years, 85. In multivariable-
adjusted analyses, compared to non-use, allopurinol use was associated with lower HR of VA of 0.82 (95% CI, 0.76–0.90).
Compared to allopurinol non-use, longer allopurinol use durations were significantly associated with lower
multivariable-adjusted HR for VA: 1–180 days, 0.96 (95% CI, 0.85–1.08); 181 days to 2 years, 0.76 (95% CI, 0.68–0.85);
and > 2 years, 0.72 (95% CI, 0.60–0.87). Multiple sensitivity analyses adjusting for cardiac conditions, anti-arrhythmic
drugs and alternate definitions confirmed our findings with minimal/no attenuation of estimates.
Conclusion: Allopurinol use and use duration of more than 6 months were independently associated with a lower risk
of VA. Future studies need to assess the pathophysiology of this potential benefit.
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Background
Recent studies have shown that hyperuricemia and gout, a
condition with hyperuricemia associated with joint inflam-
mation and/or renal manifestations, are associated with a
higher risk of coronary artery disease (CAD), acute cardio-
vascular events including myocardial infarction (MI) and
stroke, and cardiovascular mortality [1–8]. Emerging data
suggest that gout and hyperuricemia may also be associated
with cardiac arrhythmias such as atrial fibrillation [9–11].
Ventricular arrhythmias (VA) occur commonly after
an acute MI, but are also seen in patients with other car-
diac conditions such as valvular or congenital heart dis-
ease, cardiomyopathy, hypertension, and other heart
diseases [12]. The prevalence of VA (including ventricu-
lar tachycardia) in older men and women ranged from
15% to 16% in CAD, 8–9% in hypertension, valvular dis-
ease, or cardiomyopathy, and 2–3% in those without car-
diac disease [13]; VA is also associated with new
coronary events [13]. Therefore, treatment guidelines for
VA (and ventricular fibrillation (VF)) emphasize several
approaches to reduce associated morbidity and mortal-
ity, including immediate treatment using automated
external defibrillators in hospitals and the community
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settings, the use of anti-arrhythmic drugs, and the use of
implantable cardioverter-defibrillator, ablation, and re-
vascularization surgery [14, 15].
A recent analysis of the Aspirin Myocardial Infarction
Trial that examined mortality rates following daily aspirin
administration over 3 years in individuals with documented
MI, showed that gout treatments may have had beneficial
effects [4]. Compared to MI patients without gout, only MI
patients with untreated gout had higher all-cause mortality
and CHD mortality, while the risk was not increased in pa-
tients with gout treated with gout medications (allopurinol,
colchicine, or probenecid) [4]. An observational study re-
ported that allopurinol use was associated with a reduction
of the risk of incident atrial fibrillation in the elderly [16].
Together, these data raise an important question: Can allo-
purinol use reduce the risk of VA?
Animal study data suggest that allopurinol may prevent
VA. In both rat and guinea pig models of ischemia-
reperfusion injury, allopurinol treatment reduced the
incidence of VA, VF, and possibly mortality [17–19]. This
efficacy correlated with significant attenuation of reperfusion-
induced transmural conduction delay [18]. Proposed
mechanisms for allopurinol’s anti-arrhythmic action
include (1) an anti-oxidant action [20], via endothelial
nitric oxide synthase reduction [21] that likely
underlies the noted improvement of endothelial func-
tion [22–25]; (2) an anti-ischemic action [26] and as-
sociated reduction in blood pressure [27, 28]; and (3)
the reduction of left ventricular mass [29, 30] and
pressure overload [31]. Given this basic science discovery,
our recent finding of a beneficial effect of allopurinol use
on the risk of atrial fibrillation [16], and findings of mor-
tality reduction with gout treatment after MI in the As-
pirin Myocardial Infarction Trial [4], we hypothesized
that allopurinol use will be associated with a reduc-
tion in the risk of VA.
To our knowledge, there are no published human studies
addressing this question. Therefore, we aimed to assess,
whether (1) allopurinol use was associated with a lower
risk/hazard of VA; and (2) allopurinol use duration was as-
sociated with a lower risk/hazard of VA. In an exploratory
analysis, we assessed whether the risk reduction in VA with
allopurinol use varied by previous MI, and other cardiac
conditions that are risk factors for VA, and explored the as-
sociation of allopurinol with the risk of VF.
Methods
Study cohort and the population of interest
We conducted a retrospective cohort study using a 5%
random sample of persons who were Medicare benefi-
ciaries at any point in 2006–2012, using the same data-
set and a similar protocol to a study previously
published [16]. These data were obtained from the
Centers for Medicare and Medicaid Services Chronic
Condition Data Warehouse. The Medicare 5% random
sample file contains all insurance claims for each benefi-
ciary and has been widely used for epidemiological re-
search [32, 33]. We abstracted the following data from
each of the respective files: (1) a beneficiary summary
file which has demographic information, birthdate, death
date, sex, race, and monthly entitlement indicators
(A/B/C/D); (2) a part D file, which has information on
prescription claims, dose, supply, drug name; and (3)
inpatient and outpatient claim files, which contain the
diagnosis codes for each claim and claim dates. In order
to be eligible, beneficiaries had to reside in the US from
2006–2012, be enrolled in Medicare fee-for-service with
pharmacy coverage (Parts A, B, and D) and not enrolled
in a Medicare Advantage Plan, and receive a new
treatment with allopurinol (see following section for
definition). The Institutional Review Board at the University
of Alabama at Birmingham approved the study; informed
consent was waived as this was a database analysis.
Allopurinol treatment definition
A beneficiary began an allopurinol treatment episode by
filling an allopurinol prescription, provided they had not
filled an allopurinol prescription in the previous 365 days.
Days of exposure were calculated based on the days
supply variable provided in the Medicare Part D file and
included a 30 day residual period. For example, if a pa-
tient received a 90-day supply, then we considered them
exposed for 120 days; 90 days of supply plus 30 days of
residual biological effect. The purpose was two-fold, first
to capture inconsistent medication adherence, and second
to account for any residual protective biologic effects of
the medication itself. If the person filled another prescrip-
tion prior to the end of the 30-day residual period, then
we considered this as one continuous treatment episode
and a new 30-day residual period would begin when the
supply for the second prescription ran out. If the person
did not fill another prescription, then the first allopurinol
treatment episode would end and a second episode would
not commence until the next filled prescription. We
defined allopurinol treatment duration as “none”, “1–180
days”, “181 days to 2 years”, and “>2 years”, as determined
a priori to reflect short, intermediate and long-term use,
similar to a previous study [16]. Subjects contributed to
the “none” category during periods where they were not
in an allopurinol treatment episode.
Study covariates and potential confounders
Study covariates and potential confounders included age,
sex, race, common cardiac medications (statins, diuretics,
ACE inhibitors, beta-blockers), aspirin and specific anti-
arrhythmic drugs (digoxin, calcium channel blockers,
amiodarone, flecainide, and ranolazine), common con-
ditions associated with ventricular arrhythmias (CAD,
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cardiomyopathy-dilated or hypertrophic, congestive
heart failure, congenital heart disease, valvular heart dis-
ease, renal failure, dialysis, sarcoidosis, hyperkalemia), and
Charlson–Romano comorbidity index score, a valid meas-
ure of medical comorbidity [34].
Study outcome
The outcome of interest was the occurrence of incident
VA. Beneficiaries were required to have no diagnosis of
VA in a 365-day baseline period before the initiation of
allopurinol use. Incident VA after the initiation of a new
allopurinol prescription was identified based on the
occurrence of the International Classification of Diseases,
ninth revision, common modification (ICD-9-CM) codes
(427.1, 427.2, 427.4x, 427.5, 427.60, or 427.69) in the
Medicare claims, a modified list of codes based on a
validated approach with a positive predictive value of 92%
to 100% [35, 36].
Eligible beneficiaries were followed beginning on the
earliest allopurinol treatment date in the study period
and ending on first occurrence of losing full Medicare
coverage, VA diagnosis, death, or end of study period
(December 31, 2012). If a beneficiary lost and regained
Medicare coverage during the study period, then they
were eligible to reenter and contribute more treatment
episodes. Patients could contribute multiple allopurinol
treatment episodes during different time periods. Sum-
mary statistics were assessed for patients with and
without incident VA. We calculated crude incident rates
of VA by allopurinol use (yes vs. no) and the duration of
allopurinol use.
Statistical analyses
The main analysis assessed the association of allopurinol
use and incident VA, and the duration of allopurinol use
and incident VA, analyzed using separate Cox propor-
tional hazards regression models. We performed univari-
ate and multivariable-adjusted analyses, accounting for
important covariates and confounders listed in the
section above (demographics, comorbidity, common car-
diac medications, and conditions). To account for the
correlation due to patients contributing multiple treat-
ment episodes, we used the Huber–White “Sandwich”
variance estimator to calculate robust standard errors
for the parameter estimates [37]. We calculated hazard
ratios (HR) and 95% confidence intervals (CI).
Sensitivity analyses were conducted for allopurinol use
and the duration of allopurinol use by (1) replacing the
Charlson–Romano score with specific risk factors for
VA (conditions associated with VA; sensitivity analysis
1); (2) replacing the Charlson–Romano score with
specific risk factors for VA (as in previous sensitivity
analyses), and adjusting for aspirin and anti-arrhythmic
drugs (digoxin, calcium channel blockers, amiodarone,
flecainide, and ranolazine; sensitivity analysis 2); (3)
using a different set of ICD-9 codes (427.1, 427.2, 427.4,
427.41, 427.42, 427.5, 798, 798.1, and 798.2) based on
the study by Hennessey et al. [35] (sensitivity analysis 3);
and (4) adjusting additionally for anti-arrhythmic medi-
cations (mexilitine, propafenone and dofetilide; sensitiv-
ity analysis 4). We considered other anti- arrhythmic
drugs, including quinidine and procainamide, but a low
frequency of use precluded their inclusion in the model.
Subgroup analyses were performed for each of the
specific disease risk factors for VA, and by the history
of previous MI to better understand whether the risk
reduction varies by the underlying etiology for VA or
by prior MI. We analyzed MI separately, since MI is
a discrete event that has a well-established association
with VA, which is associated with significant morbid-
ity and mortality. We anticipated much fewer events
for VF (ICD-9 code, 427.4, 427.41 and 427.42), and
anticipating lower power, we planned an exploratory
analysis for this outcome. We also performed sub-
group analyses by the underlying diagnosis (gout vs.
non-gout) to assess differential benefit by diagnosis
and for patients who were not receiving anti-arrhythmic
or cardio-protective drugs, to assess the protective
effect associated with xanthine oxidase inhibition with
allopurinol.
Results
Clinical and demographic characteristics
The study flow chart is shown in Fig. 1. Of the 28,755
episodes of new allopurinol use, 2538 were associated
with incident VA during the follow-up (8.8%). Allopur-
inol daily dose was < 200 mg/day in 46%, 200–299 mg/
day in 18%, and ≥ 300 mg/day in 36%. The underlying
diagnosis was gout in 74%, asymptomatic hyperuricemia
in 5%, renal calculi in 2%, and other diagnoses in 19%.
Of these, 1525 VA episodes occurred during days of
allopurinol exposure and 1013 occurred during periods
of no allopurinol exposure. Among patients with inci-
dent VA, 54% were male, 78% were White, 40% were in
Southern USA, and the mean Charlson–Romano comor-
bidity score was 4.8 (Table 1). We noted a significant
difference in age, sex, race, Charlson–Romano scores, and
region between VA and non-VA groups (Table 1). The
crude incidence of ventricular arrhythmias/1,000,000
person-days declined as the duration of allopurinol use
increased: 1–180 days, 151; 181 days to 2 years, 105;
and > 2 years, 85 (Additional file 1: Appendix 1).
Association of allopurinol use with ventricular
arrhythmias
In multivariable-adjusted analyses, compared to allopur-
inol non-use, allopurinol use was associated with signifi-
cantly lower HR of 0.82 of VA (95% CI, 0.76–0.90), as
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were allopurinol use durations of > 6 months: 1–180 days,
0.96 (95% CI, 0.85–1.08); 181 days to 2 years, 0.76 (95%
CI, 0.68–0.85); and > 2 years, 0.72 (95% CI, 0.60–0.87)
(Model 1; Table 2). Other factors associated with signifi-
cantly higher hazard ratios of VA are shown in Table 2.
Several multivariable-adjusted hierarchical sensitivity
analyses confirmed the main study findings with no/
minimal change in estimates or the level of significance,
including adjustment for diseases that are known risk
factors for VA instead of Charlson index score
(sensitivity analysis 1; Table 3); additional adjustment for
aspirin, digoxin, calcium channel blockers, amiodarone,
flecainide, and ranolazine revealed the same hazard ratio
as in previous analysis (sensitivity analysis 2; data not
shown). Rerunning these models with a different set of
ICD-9 codes for VA based on the study by Hennessey et
al. [35] (sensitivity analysis 3; Additional file 1: Appendix
2) or additional adjustment for anti-arrhythmic medica-
tions, mexilitine, propafenone, and dofetilide (sensitivity
analysis 4; Additional file 1: Appendix 3), confirmed the
main results.
Exploratory subgroup analyses by VA risk factors,
previous MI, race/sex, and for VF
We found that allopurinol-VA associations were similar
in cohorts with and without each VA risk factor with
three exceptions, i.e., hazard-reduction was slightly more
in patients without CAD, heart failure, or dialysis com-
pared to patients with each respective condition
(Table 4); differences in statistical significance was likely
due to sample size differences between groups with
versus without each condition.
The hazard ratios for allopurinol use for VA were
similar in patients with versus without previous MI, but
the results for allopurinol use were not significant in
those with previous MI (Additional file 1: Appendix 4;
Fig. 2). We found that longer allopurinol use durations,
especially allopurinol use for over 2 years, were signifi-
cantly associated with lower HR for VA in both patients
with or without previous MI, and hazard reduction was
more impressive in patients with previous MI
(Additional file 1: Appendix 4; Fig. 2). Black race and
male sex were associated with higher hazard of VA
versus counterparts (Additional file 1: Appendix 5).
We observed 245 episodes of VF during follow up, 96
were during allopurinol exposed days and 149 were not;
we noted 29,730 allopurinol episodes without VF. In an
exploratory multivariable-adjusted analysis of VF we
found that Charlson–Romano score was the only
covariate significantly associated with an increased hazard
of VA, while allopurinol use or use duration were not
significantly associated (Additional file 1: Appendix 6).
Exploratory subgroup analyses by diagnosis and in
patients not receiving anti-arrhythmic or cardio-
protective drugs
Allopurinol use reduced the hazard of VA in patients
with gout, HR was 0.81 (95% CI, 0.73–0.90); hazard re-
duction in those without gout (a much smaller sample)
was not significant, 0.89 (95% CI, 0.71–1.10) (Additional
file 1: Appendix 7). Allopurinol use duration was signifi-
cantly associated with reduction of hazard of VA in
patients with gout, similar to the main analysis
(Additional file 1: Appendix 7). In analyses limited to pa-
tients not receiving anti-arrhythmic or cardio-protective
drugs, allopurinol use and use duration were associated
Fig. 1 Patient selection flow chart. The flow chart shows the selection of
new allopurinol exposure episodes after applying all the eligibility criteria,
including an absence of VA and the absence of any allopurinol filled
prescription in the baseline period of 365 days (new user design). We
found 28,755 new allopurinol exposure episodes in 26,905 patients. Of
these, 2538 ended in incident VA and 26,217 ended without incident VA.
* We followed each eligible patient with a new filled allopurinol
prescription until the patient lost full Medicare coverage, had VA
(the outcome of interest), died or reached the each of the study period
on December 31, 2012, whichever came first. For some of these patients,
the VA occurred on days covered by allopurinol exposure (n = 1525), yet
other patients had periods of no allopurinol exposure after an initial
qualifying allopurinol exposure during which VA occurred (n = 1013). Nb
Number of beneficiaries, TE treatment episodes, Np Number of
allopurinol prescriptions, NE Number of qualified episodes of new
allopurinol prescriptions, VA Ventricular arrhythmia
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significantly with the hazard of VA, as in the main ana-
lysis (Additional file 1: Appendix 8).
Discussion
In this study of a nationally representative sample of
older Americans, we made several novel observations.
We found that allopurinol use was independently associ-
ated with a lower hazard of incident VA. We also found
that, compared to allopurinol non-use, allopurinol use
durations greater than 6 months were associated with
significant reduction in the hazard of incident VA.
Associations of allopurinol use and use duration with
hazard reduction of VA were confirmed in patients with
gout, and for patient subgroups who were not on anti-
arrhythmic or cardio-protective drugs. The hazard re-
duction of VA with allopurinol differed by the history of
previous MI and the presence of other diseases, which
are known risk factors for VA. These novel study find-
ings deserve further elaboration and discussion.
Recent experimental evidence using animal models of
ischemia-reperfusion injury showed that treatment with
allopurinol reduced the incidence of VA and possibly
mortality [17–19]. To our knowledge, this is the first
study in humans to show that, compared to non-use,
allopurinol use was associated with a 18% reduction
(clinically relevant) in the hazard of incident VA and
longer durations of allopurinol use of 181 days to 2 years
and more than 2 years were associated with hazard
reductions of 24% and 28%, respectively (Table 3). In the
absence of prior studies in humans, no comparisons
could be done. Animal studies support allopurinol’s anti-
arrhythmic action in ischemia-reperfusion injury models
[17–19], including a placebo-controlled study of allopur-
inol [17]. The mechanism of hazard reduction of VA
with allopurinol is unknown. We speculate that it may
be related to the significant attenuation of reperfusion-
induced transmural conduction delay, as noted with
allopurinol use in a guinea pig ischemia-reperfusion
injury model [18]. Other proposed mechanisms may be
related to other noted beneficial effects of allopurinol,
including associated anti-oxidant action [20, 21], an
anti-ischemic action [26], blood pressure reduction [27,
28], improvement of endothelial function [22–25], and
reduction of left ventricular mass [29, 30]. Some of
these processes may be sequential and many are likely
on the causative pathway of VA.
VA often occur in patients with CAD and cardiac
dysfunction, including heart failure [13]. The generation
of reactive oxygen species in these disorders can contrib-
ute to induction of arrhythmias, via multiple mechanisms,
Table 1 Demographic and clinical characteristics of episodes of new allopurinol users (baseline with no ventricular arrhythmias;
baseline was 365 days)
All new allopurinol
use episodes
Allopurinol new use episodesa associated with versus without
ventricular arrhythmias (VA) during the follow-up
P value
VA No VA
Total, N (episodes) 28,755 2538 26,217
Age, mean (SD) 76.6 (7.4) 77.2 (7.3) 76.5 (7.5) < 0.0001
Sex, N (%) < 0.0001
Male 14,074 (48.9%) 1369 (53.9%) 12,705 (48.5%)
Female 14,681 (51.1%) 1169 (46.1%) 13,512 (51.5%)
Race/Ethnicity, N (%) < 0.0001
White 22,693 (78.9%) 1976 (77.9%) 20,717 (79.0%)
Black 3510 (12.2%) 382 (15.1%) 3128 (11.9%)
Hispanic 606 (2.1%) 49 (1.9%) 557 (2.1%)
Asian 1268 (4.4%) 89 (3.5%) 1179 (4.5%)
Native American 97 (0.3%) 7 (0.3%) 90 (0.3%)
Other/unknown 581 (2.0%) 35 (1.4%) 546 (2.1%)
Region, N (%) 0.03
Northeast 4607 (16.0%) 460 (18.1%) 4147 (15.8%)
Midwest 7315 (25.4%) 626 (24.7%) 6689 (25.5%)
South 11,563 (40.2%) 1003 (39.5%) 10,560 (40.3%)
West 5270 (18.3%) 449 (8.5%) 4821 (18.4%)
Charlson–Romano comorbidity score 3.65 (3.25) 4.79 (3.40) 3.54 (3.21) < 0.0001
SD, standard deviation
aAll data are at episode level
Significant P values are in bold
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Table 2 Association of risk factors with hazard of ventricular arrhythmias in patients who received allopurinol with no baseline
ventricular arrhythmias before the index date of allopurinol episode
Univariate Multivariable adjusted (Model 1) Multivariable adjusted (Model 2)
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (in years)
65 to < 75 Ref Ref Ref
75 to < 85 1.25 (1.15–1.36) < 0.0001 1.19 (1.09–1.30) < 0.0001 1.19 (1.09–1.30) < 0.0001
≥ 85 1.43 (1.28–1.60) < 0.0001 1.37 (1.22–1.53) < 0.0001 1.37 (1.22–1.53) < 0.0001
Sex
Male Ref Ref Ref
Female 0.81 (0.75–0.87) 0.50 0.74 (0.68–0.80) < 0.0001 0.73 (0.68–0.80) < 0.0001
Race
White Ref Ref Ref
Black 1.32 (1.19–1.48) < 0.0001 1.30 (1.16–1.45) < 0.0001 1.29 (1.15–1.44) < 0.0001
Other 0.80 (0.69–0.94) 0.005 0.78 (0.67–0.91) 0.002 0.78 (0.67–0.90) 0.001
Charlson–Romano score, per unit change 1.15 (1.14–1.16) < 0.0001 1.14 (1.13–1.16) < 0.0001 1.14 (1.13–1.16) < 0.0001
Diuretics 1.12 (0.94–1.33) 0.21 1.03 (0.86–1.24) 0.72 1.03 (0.86–1.24) 0.74
Statins 0.86 (0.70–1.05) 0.13 0.79 (0.64–0.97) 0.02 0.79 (0.64–0.97) 0.02
ACE inhibitor 1.09 (0.88–1.34) 0.43 1.11 (0.90–1.38) 0.32 1.11 (0.90–1.38) 0.33
Beta blockers 1.42 (1.20–1.68) < 0.0001 1.41 (1.18–1.68) 0.0001 1.40 (1.18–1.68) 0.0001
Allopurinol use 0.86 (0.79–0.94) 0.001 0.82 (0.76–0.90) < 0.0001 – –
Allopurinol use durationa
0 days Ref – – Ref
1 to 180 days 0.99 (0.88–1.12) 0.88 – – 0.96 (0.85–1.08) 0.49
181 days to 2 years 0.81 (0.72–0.90) 0.0002 – – 0.76 (0.68–0.85) < 0.0001
> 2 years 0.74 (0.62–0.90) 0.002 – – 0.72 (0.60–0.87) 0.001
Significant hazards ratios and P values are in bold
aBased on person day count
Model 1 = Allopurinol use + age + race + sex + Charlson–Romano score + beta blockers + diuretics + ACE inhibitors + statins
Model 2 = Allopurinol duration + age + race + sex + Charlson–Romano score + beta blockers + diuretics + ACE inhibitors + statins
HR hazard ratio, CI confidence interval, Ref referent category
Table 3 Sensitivity Analysis 1: Association of risk factors with hazard of ventricular arrhythmias adjusted for specific disease risk
factors for ventricular arrhythmias instead of Charlson index
Multivariable adjusted (Model 3) Multivariable adjusted (Model 4)
HR (95% CI) P value HR (95% CI) P value
Allopurinol use 0.82 (0.75–0.89) < 0.0001 – –
Allopurinol use durationa
0 days (non-use) – – Ref
1–180 days – – 0.92 (0.82–1.04) 0.18
181 days to 2 years – – 0.76 (0.68–0.84) < 0.0001
> 2 years – – 0.78 (0.65–0.94) 0.009
aBased on person day count
Model 3 = Allopurinol use + age + race + sex + beta blockers + diuretics + ACE inhibitors + statins + CAD + cardiomyopathy + heart failure + congenital heart disease
+ valvular heart disease + renal failure + dialysis + sarcoidosis + hyperkalemia
Model 4 = Allopurinol duration + age + race + sex + beta blockers + diuretics + ACE inhibitors + statins + CAD + cardiomyopathy + heart failure + congenital heart
disease + valvular heart disease + renal failure + dialysis + sarcoidosis + hyperkalemia
Significant hazards ratios and P values are in bold
HR hazard ratio, CI confidence interval, Ref referent category
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including the alteration of cardiac ionic channels [38] and
cardiac cell death associated ventricular dysfunction [39].
Oxidative-stress mediated tissue injury during ischemia
and reperfusion may be associated with both ischemia and
reperfusion-induced arrhythmias [17]. Xanthine oxidase
has been implicated in cardiovascular disease and
xanthine oxidase inhibition for its treatment [24, 40–42].
Allopurinol inhibits xanthine oxidase activity, which in
turn inhibits superoxide radical production and reduces
oxidative stress [43]. Allopurinol’s anti-oxidant effect
likely leads to an improvement in endothelial function
and possibly has an anti-ischemic effect, which might
prevent left ventricular hypertrophy. In particular, both
the endothelial function improvement [22–25], and the
anti-ischemic effects [26] associated with the use of
allopurinol may be the key mechanisms related to this
anti-arrhythmic effect.
Our observation may have practical implications,
although they need further confirmation before a wide-
spread implementation. Allopurinol is a well-known
effective, affordable treatment for gout, the most com-
mon inflammatory arthritis in adults, affecting 5% of
adult Americans [44]. The emerging evidence of cardio-
protective action of allopurinol provides a greater
urgency for optimal use of allopurinol in all patients
with gout (except rare instance). This observation of
Table 4 Exploratory subgroup analysis of the main analyses: multivariable-adjusted hazard ratio of ventricular arrhythmias (VA) for
allopurinol use and for the duration of allopurinol use by each VA risk factor
Allopurinol use (using model 5) HR (95% CI) [P value] Allopurinol use duration (using model 6) HR (95% CI) [P value]
No Yes 0 day 1 to 180 days 181 days to 2 years > 2 years
Coronary artery disease
No 1 0.60 (0.47–0.78) [0.0001] Ref 0.71 (0.47–1.06) [0.09] 0.57 (0.42–0.83) [0.002] 0.45 (0.25–0.81) [0.007]
Yes Ref 0.85 (0.77–0.95) [0.003] Ref 0.97 (0.84–1.12) [0.64] 0.79 (0.69–0.90) [0.001] 0.79 (0.62–0.99) [0.04]
Cardiomyopathy-dilated or hypertrophic
No Ref 0.80 (0.71–0.90) [0.0002] Ref 0.91 (0.77–1.07) [0.26] 0.75 (0.65–0.88) [0.0002] 0.71 (0.55–0.91) [0.007]
Yes Ref 0.84 (0.71–0.99) [0.04] Ref 0.95 (0.75–1.21) [0.68] 0.77 (0.62–0.96) [0.02] 0.73 (0.46–1.15) [0.17]
Heart failure
No Ref 0.74 (0.65–0.85) [< 0.0001] Ref 0.88 (0.73–1.07) [0.20] 0.67 (0.55–0.81) [< 0.0001] 0.66 (0.50–0.89) [0.006]
Yes Ref 0.89 (0.78–1.01) [0.08] Ref 0.98 (0.81–1.18) [0.82] 0.84 (0.74–0.99) [0.04] 0.79 (0.57–1.10) [0.16]
Congenital heart disease
No Ref 0.82 (0.74–0.90) [< 0.0001] Ref 0.93 (0.81–1.06) [0.26] 0.76 (0.68–0.87) [< 0.0001] 0.73 (0.59–0.91) [0.005]
Yes Ref 0.80 (0.41–1.57) [0.52] Ref 1.36 (0.60–3.11) [0.47] 0.52 (0.18–1.44) [0.21] 0.00 (0.0–0.0) [< 0.0001]
Valvular heart disease
No Ref 0.82 (0.74–0.92) [0.0004] Ref 0.94 (0.81–1.09) [0.39] 0.77 (0.67–0.88) [0.0002] 0.74 (0.58–0.94) [0.01]
Yes Ref 0.78 (0.63–0.97) [0.025] Ref 0.92 (0.68–1.24) [0.56] 0.72 (0.58–0.95) [0.018] 0.66 (0.38–1.13) [0.13]
Renal failure
No Ref 0.81 (0.67–0.98) [0.03] Ref 0.93 (0.70–1.24) [0.62] 0.79 (0.62–1.01) [0.06] 0.63 (0.42–0.96) [0.03]
Yes Ref 0.81 (0.73–0.91) [0.0003] Ref 0.93 (0.80–1.09) [0.37] 0.75 (0.65–0.86) [< 0.0001] 0.75 (0.58–0.97) [0.03]
Dialysis
No Ref 0.81 (0.73–0.89) [< 0.0001] Ref 0.90 (0.79–1.03) [0.14] 0.76 (0.67–0.87) [< 0.0001] 0.73 (0.53–0.90) [0.004]
Yes Ref 1.36 (0.54–3.43) [0.52] Ref 2.43 (1.03–5.69) [0.04] 0.73 (0.19–2.77) [0.64] 0.00 (0.0–0.0) [< 0.0001]
Sarcoidosis
No Ref 0.81 (0.74–0.89) [< 0.0001] Ref 0.93 (0.81–1.06) [0.29] 0.76 (0.67–0.85) [< 0.0001] 0.72 (0.58–0.90) [0.003]
Yes Ref 0.86 (0.13–5.58) [0.88] Ref 0.73 (0.05–11.2) [0.82] 1.11 (0.11–11.41) [0.93] 0.00 (0.0–0.0) [< 0.0001]
Hyperkalemia
No Ref 0.81 (0.73–0.91) [0.0002] Ref 0.92 (0.78–1.08) [0.31] 0.76 (0.66–0.88) [0.0001] 0.73 (0.57–0.93) [0.01]
Yes Ref 0.82 (0.68–0.99) [0.04] Ref 0.95 (0.73–1.22) [0.68] 0.76 (0.59–0.97) [0.03] 0.67 (0.42–1.08) [0.10]
Model 5 = Allopurinol use + age + race + sex + beta blockers + diuretics + ACE inhibitors + statins + CAD + cardiomyopathy + heart failure + congenital heart disease
+ valvular heart disease + renal failure + dialysis + sarcoidosis + hyperkalemia + aspirin + digoxin + calcium channel blockers + amiodarone + flecainide + ranolazine
Model 6 = Allopurinol duration + age + race + sex + beta blockers + diuretics + ACE inhibitors + Statins + CAD + cardiomyopathy + heart failure + congenital heart
disease + Valvular heart disease + renal failure + dialysis + sarcoidosis + hyperkalemia + aspirin + digoxin + calcium
channel blockers + amiodarone + flecainide + ranolazine
Significant hazards ratios and P values are in bold
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anti-arrhythmic action may lead to a preference of
allopurinol over other urate-lowering agents in gout
and related conditions. It is possible that there is an
even greater advantage of allopurinol use in patients
with gout and a concomitant well-known pro-arrhythmic
condition. Our findings indicate that there may be a
potential role for allopurinol as a xanthine-oxidase
inhibitor beyond the joint, including a protective role
in preventing VAs in patients with myocardial ische-
mia and damage.
The estimates for allopurinol use and use duration
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Fig. 2 (See legend on next page.)
Singh and Cleveland BMC Medicine  (2017) 15:59 Page 8 of 11
sensitivity analyses. This observation of an anti-arrhythmic
effect is similar to the recent observations of poten-
tially cardioprotective effects of allopurinol in the
elderly [16, 45, 46]. Longer duration of allopurinol
use was associated with more VA hazard reduction, repre-
senting a dose effect with a magnitude similar to that
noted with the associated reduction of myocardial infarc-
tion, stroke, or atrial fibrillation [16, 45, 46].
An interesting observation was that the beneficial effect
of allopurinol use was similar for subgroup analyses for
most diseases that are risk factors for VA, including valvu-
lar heart disease, congenital heart disease, heart failure,
renal failure, dialysis, cardiopmyopathy, and hyperkalemia.
Minor differences in statistical significance seemed related
to a smaller sample size for patients with each VA risk
factor. One interesting observation was that, although
beneficial for both, allopurinol’s beneficial effect was
greater in magnitude for patients without CAD versus
with CAD, 38% versus 13% hazard reduction (model 1).
Allopurinol use was associated with statistically significant
hazard reduction for VA (18%) in patients without
previous MI, but reduction was not statistically significant
in those with previous MI (Model 5). This is not surpris-
ing since ischemia-reperfusion injury is one of the
best-described pathophysiologic associations between MI
and VA [17–19, 47–50]. Irreversible structural damage
may already have occurred in some patients with CAD/
MI, making allopurinol not as effective in patients with
CAD/MI. This finding may have important implications,
if confirmed in other studies. Additionally, a smaller
sample size for patients with MI may have made this
analysis underpowered.
We noted an association of older age and Black race with
a higher hazard of VA, confirming a similar previous find-
ing [51–53]. We also noted that older age was no longer
significantly associated with the risk of VA once the model
was adjusted for VA risk factors, such as CAD, congenital
heart disease, renal failure, and others. This indicated that
age-VA associations were not due to chronological age but
rather reflected the higher risk imparted due to specific dis-
eases that are VA risk factors, more common in the elderly.
Study findings must be interpreted considering their
strengths and limitations. An observational study design
makes our findings susceptible to confounding bias. We tried
to reduce confounding bias by including several important
patient characteristics, common cardiac medications and
adjusting for risk factor conditions for VA. We used ICD-9
diagnostic codes from Medicare claims for the assessment of
VA, which makes results liable to misclassification bias; this
likely biased our results towards null. However, similar ap-
proaches have been shown to have high positive predictive
values in a systematic review of claims-based definitions of
ventricular arrhythmias [36]. Sensitivity analysis using the
VA code algorithm with the highest positive predictive value
(92–100%) reproduced the same result as our main analysis
[35]. We realized a priori that there would be insufficient
number of VF events, making this analysis underpowered
and therefore exploratory in nature, as shown. Limited
sources and expected few data for febuxostat (regulatory
approval in 2009; another xanthine oxidase inhibitor)
prevented us from performing additional comparative effect-
iveness studies comparing febuxostat to allopurinol.
The main strength of this study lies in the potential for
generalization to the elderly US population and to all allo-
purinol new-users, regardless of the underlying diagnosis.
Our study had a large sample size and adequate number of
outcome events. Another strength is the incident (or new)
user design, which reduces bias by avoiding adjustment for
characteristics that may be in the causal pathway and allows
capture of both early and late events [54], which is important
given the study objectives. We controlled for several poten-
tial confounders (risk factors for VA; cardiac medications) to
reduce bias and conducted multiple sensitivity analyses,
which confirmed the robustness of our findings.
Conclusions
In conclusion, we found a significant association be-
tween incident allopurinol use and a lower hazard of VA
in the elderly. This result was more pronounced for lon-
ger allopurinol use durations. Results for patients with
an underlying diagnosis of gout were similar to the
entire sample of allopurinol users. We also found some
differences in VA risk reduction with allopurinol in
patients with and without CAD and previous MI.
Mechanisms of reduction of ventricular arrhythmias
with allopurinol need to be examined in future studies.
(See figure on previous page.)
Fig. 2 Examining the effect of previous myocardial infarction (MI) on the associations of allopurinol use (2a) and allopurinol use duration (2b, 2c)
with incident ventricular arrhythmias (VA). a Association of allopurinol use with VA by previous MI: Models 1 and 5. b Association of allopurinol
use duration with VA by previous MI: Model 2. c Association of allopurinol use duration with VA by previous MI: Model 6. Each solid bar
represents the hazard ratio estimate for allopurinol use (vs. non-use) for both Models 1 and 5 (panel a) or allopurinol use duration for Model 2
(panel b; multivariable model adjusted for demographics, Charlson–Romano score, beta blockers, diuretics, ACE inhibitors and statins) and
model 6 (panel c; multivariable model adjusted for demographics, beta blockers, diuretics, ACE inhibitors, statins, VA risk factor conditions, aspirin,
digoxin, calcium channel blockers, amiodarone, flecainide, and ranolazine), each panel given the presence or absence of previous MI. A hazard
ratio of 1.0 represents the reference hazard with no exposure to allopurinol. Error bars represent the 95% confidence interval for each hazard ratio
and inclusion of 1.0 in this range indicates that the hazard ratio is not significant
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Future studies should also examine the underlying
mechanisms for why the VA hazard reduction with
allopurinol varies by CAD and previous MI.
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